ABSTRACT: Introduction: Our objective was to determine the utility of motor unit number index (MUNIX) and neurophysiological index (NI) as surrogate biomarkers of disease progression in limbs without clinical signs of lower motor neuron (LMN) involvement from patients with slowly progressive amyotrophic lateral sclerosis (ALS). Methods: Patients with slowly progressive ALS and at least 1 clinically unaffected limb were prospectively enrolled. Clinical signs of LMN loss and results from hand-held dynamometer (HHD), revised ALS Functional Rating Scale (ALSFRS-R), mean-MUNIX (from 3 different muscles), and NI were longitudinally recorded. Results: Eighteen patients with 43 presymptomatic muscles were evaluated. Twenty-seven muscles remained clinically unaffected during study, with stable ALSFRS-R subscores and HHD measures. However, a significant decline in mean-MUNIX and NI was detected. Discussion: Mean-MUNIX and NI were more sensitive than clinical measures at detecting LMN loss in presymptomatic limbs from patients with slowly progressive ALS. Therefore, these electrophysiological biomarkers should be included in early study phases as meaningful outcome measures.
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Amyotrophic lateral sclerosis (ALS) is a terminal neurodegenerative disease that affects the upper motor neuron (UMN) and the lower motor neuron (LMN). ALS progression rate and phenotypes are heterogeneous, and patients frequently have muscles with intact strength for many months before the disease weakens those muscles 1 ; this is likely related to insidious motor neuron degeneration and compensatory reinnervation. 2, 3 Longitudinal presymptomatic LMN loss is presently not captured in the commonly used clinical trial outcome measures. The validation of noninvasive and reliable biomarkers of presymptomatic LMN loss is essential because a study drug may be most effective in the earliest phase of motor neuron injury, and intervention may affect the LMN biomarker measure prior to the clinical measure. 4 Motor unit number index (MUNIX) 5, 6 is an electrophysiological index that directly correlates with the number of functional motor units in a given muscle and has comparable performance to validated motor unit number estimation (MUNE) techniques in tracking LMN loss in ALS. [7] [8] [9] MUNIX is calculated by using the supramaximal compound muscle action potential (CMAP) and surface electromyography (EMG) interference pattern obtained at progressive levels of voluntary effort. 5 The technique has high reproducibility and is time efficient, enabling the evaluation of multiple muscles at a single visit. 6, 10, 11 These characteristics make MUNIX an attractive tool to track motor neuron loss and a promising candidate biomarker of disease progression in ALS. 7, 8, [10] [11] [12] [13] The utility of MUNIX to detect disease progression in presymptomatic muscles in classic forms of ALS was recently demonstrated. Lower MUNIX values were demonstrated by Fukada et al.
14 and by our group 12 in cross-sectional evaluations of muscles with normal manual strength testing in patients with ALS compared with controls. MUNIX also detected LMN loss longitudinally in muscles with normal clinical strength and was more sensitive to change than the revised ALS Functional Rating Scale (ALSFRS-R) in a multicenter study involving 49 patients with ALS. 15 The neurophysiological index (NI) is also a potential electrophysiological biomarker in ALS. 16 The NI is more sensitive than the CMAP alone to Additional supporting information may be found in the online version of this article.
demonstrate longitudinal LMN loss in ALS and has the advantage of using routine CMAP amplitude, F-wave frequency, and distal motor latency of the ulnar-nerve innervated abductor digiti minimi (ADM) muscle in a simple formula. 16, 17 The sensitivity of the NI to track LMN loss in presymptomatic patients with ALS has not been reported.
Slowly progressive variants of ALS may present with clinically intact muscles (absence of fasciculations, normal muscle bulk, and full muscle strength) for a longer period of time than usually occurs in classic forms of ALS, and the performance of MUNIX and NI to detect disease progression in this patient subpopulation is unknown. We studied the prospective changes in MUNIX and NI in presymptomatic limbs in an ALS cohort with slowly progressive disease and contrasted them to commonly used research trial clinical measures (ALSFRS-R subscores 18 and handgrip strength 19 ). 20 presenting with (1) onset of weakness or dysarthria within 2.5 years, (2) slow disease progression, and (3) at least 1 limb with no clinical evidence of LMN dysfunction (also referred to as presymptomatic limb or muscle) as assessed by a neuromuscular neurologist. Slow disease progression was defined as a change in the ALSFRS-R less than 1 unit per month. 21 Individuals with no functional deficits score 48 on this ordinal scale, with lower scores indicating poorer function. 18 To calculate the estimated rate of disease progression at the baseline visit, we imputed a normal ALSFRS-R of 48 at onset time of weakness or bulbar dysfunction and measured the ALSFRS-R score at first study visit. 21 Clinically intact LMN function was defined as absence of fasciculations, normal muscle bulk, and full muscle strength (grade 5, Medical Research Council) in the shoulder abductors, elbow flexors, elbow extensors, wrist extensors, finger extensors, index finger abductors, and flexors of the thumb distal phalynx in the upper extremity or hip flexors, hip extensors, hip abductors and adductors, knee extensors and flexors, ankle dorsiflexors, and plantar flexors in the lower extremity. Evidence of UMN dysfunction without weakness was permitted as long as no LMN dysfunction was detected. Patients were excluded if they had other diseases that could affect LMN function or cooperation with study procedures, such as a polyneuropathy, focal nerve entrapment, symptomatic radicular pain, or frontotemporal dementia. Electrophysiological studies were conducted in 1 arm (ADM, abductor pollicis brevis [APB]) and/or 1 leg (tibialis anterior [TA]), provided that no clinical LMN involvement was present, as determined during the baseline visit.
MATERIALS AND METHODS

Standard
Age and sex-matched participants with no family history of neuromuscular diseases, diabetes, hypothyroidism, or malignancy were recruited (control group) and were used to determine normal parameters for clinical and electrophysiological measures. Part of this control cohort has been previously published. 12 Measures. Participants underwent clinical and electrophysiological assessments during 3 consecutive, routine follow-up visits in our clinic. At each study visit, the clinical absence or presence of LMN signs was recorded, and the ALSFRS-R score, handgrip strength, mean-MUNIX, and NI measures were obtained.
Handgrip strength was measured ipsilateral to the selected APB and ADM muscles by using the Jamar hydraulic hand-held dynamometer (HHD; Sammons Preston Rolyan, Bolingbrook, IL). 19 The instrument was calibrated according to the manufacturer's instructions, and the isometric force was scored in kilograms. The mean of 3 maximum voluntary handgrip contractions was recorded.
The validated Portuguese version of the ALSFRS-R was used at each visit. 18, 22 We analyzed ALSFRS-R arm subscore (summation of the items handwriting and cutting food, maximum 8 points when there was no functional impairment) and ALSFRS-R leg subscore (summation of the items walking and climbing stairs, maximum 8 points when there was no functional impairment).
Electrophysiological measures included CMAP and MUNIX of the TA, APB, and ADM and the NI. All tests were performed by the same neurophysiology-boardcertified neurologist. The MUNIX procedure of the APB, ADM, and TA muscles performed in this study was previously described in detail elsewhere. 12, 23 To improve the reproducibility, we chose to determine the MUNIX value in 3 consecutive trials for each muscle, and to use the averaged result (mean-MUNIX) throughout the study. 23, 24 The NI was determined by a mathematical model using the Mwave, distal motor latency, and F-wave frequency in the ulnar territory recorded at the ADM muscle: (M-wave amplitude/distal motor latency) 3 (F-wave persistence after 20 stimuli). 16, 17 To assess reproducibility for quality purposes, the coefficient of variability (COV) of mean-MUNIX and NI was calculated and reported as described in the Supporting Information or as published elsewhere. 12 Statistical Analysis. To determine the normal parameters for this study, the baseline measures of the mean-MUNIX (TA, APB, and ADM), NI, and HHD from the control individuals were obtained and compared with baseline measures from patients with ALS. The time period from the baseline visit to the last visit in which LMN signs were absent (month 0) was designated as the presymptomatic interval. Longitudinal absolute and relative values of the mean-MUNIX and NI were analyzed and compared with the relative measures of the ALSFRS-R subscores and HHD. Two-level linear mixed-effect models were used to calculate the relative rate of decline of mean-MUNIX, NI, HHD, and ALSFRS-R total and subscore values during the presymptomatic and symptomatic intervals. In this model, we used the relative decline rate as the dependent variable along with the type of measure (mean-MUNIX, NI, HHD, ALSFRS-R) and time (in months) as the fixed effects. Participants were defined as the random effect.
Proportions were calculated for categorical variables. Mean 6 SD was computed for continuous variables. Decline rates and difference of means were represented with 95% confidence intervals. Comparisons were performed by using two-sample Student's t test or v 2 test for proportions, as appropriate, in STATA version 14 (StataCorp, College Station, TX). To determine the absolute threshold of mean-MUNIX that is associated with higher likelihood of detecting clinical LMN involvement, a receiver operating characteristic (ROC) curve was generated in SAS (Cary, NC) Studio. Two-sided P < 0.05 was considered significant.
RESULTS
Baseline Clinical and Electrophysiological Characteristics.
Eighteen patients (13 women) with slow ALS disease progression (mean ALSFRS-R decline rate of 0.5 unit per month) and mean age of 61 6 6 years with 43 presymptomatic muscles (15 TA, 14 APB, and 14 ipsilateral ADM) were enrolled. The majority (61%) of patients had bulbar-onset ALS with mean disease duration from symptom onset of 15 6 8 months and mean ALSFRS-R score of 41. Sixty-three muscles (21 TA, 21 APB, and 21 ADM) from 21 asymptomatic, age-and sex-matched volunteers were enrolled in the control group. The reproducibility of mean-MUNIX in this control population was previously published. 12 The reproducibility of the NI as measured by the COV in the control group was 2.3 6 8.1 (Supp. Info.). Demographics are summarized in Table 1 . After the baseline visit, 15 patients completed 2 follow-up visits in the interval between 3 and 15 months, and 3 patients had only 1 follow-up visit at 3 months. Electrophysiological procedures were well tolerated, and testing at each visit was completed in 30-40 min.
Compared with controls, patients with ALS had presymptomatic muscles with significantly lower mean-MUNIX and NI values, measured at baseline study visit (Fig. 1A-D) . The baseline HHD values were not statistically different in patients with ALS compared with controls (P > 0.05; Fig. 1E ).
Longitudinal Mean-MUNIX, NI, and Clinical Measures.
Twenty-seven presymptomatic muscles (9 TA, 9 APB, and 9 ADM) from 9 patients with bulbaronset remained asymptomatic with no clinical evidence of LMN loss for a period up to 15 months (defined as presymptomatic interval). Sixteen presymptomatic muscles from 8 spinal-onset and 2 bulbar-onset ALS patients had clinically detectable LMN loss at the first follow-up visit (Fig. 2) . The absolute values of mean-MUNIX from all muscles and NI revealed a steady decline during the presymptomatic and symptomatic intervals (Fig. 2) . Absolute mean-MUNIX values below the threshold of 89 increased the likelihood of detecting clinical signs of LMN dysfunction in the TA, APB, or ADM muscles (v 2 38, degrees of freedom 1, P < 0.001; see Supp. Info. for ROC curve). Mean-MUNIX had a steeper monthly relative decline rate compared with the decline rate of NI, CMAP, and clinical measures (ALSFRS-R and HHD) during the presymptomatic interval (Table 2) . During the symptomatic interval, the NI had faster relative decline (Table 2 ).
In the upper extremities, APB mean-MUNIX had a steeper monthly decline rate compared with ADM mean-MUNIX and NI during the presymptomatic interval (Table 2) . Mean-MUNIX of the APB had significantly lower relative mean values ADM, abductor digiti minimi; ALS, amyotrophic lateral sclerosis; ALSFRS-R, revised ALS Functional Rating Scale; APB, abductor pollicis brevis; CI95%, confidence interval 95%; TA, tibialis anterior.
*Estimated ALSFRS-R decline rate: (48 2 [baseline ALSFRS-R])/(interval in months between baseline visit and symptom onset).
†
Prospective ALSFRS-R decline rate during the study was determined by a linear mixed-effect model.
compared with HHD and ALSFRS-R arm subscores (Fig. 3) . The ALSFRS-R arm subscore remained stable during the presymptomatic interval, whereas handgrip strength slightly declined despite normal manual strength test results (Fig. 3, Table 2 ). In the lower extremities, TA mean-MUNIX also declined during the presymptomatic interval of these patients with bulbar-onset ( Table 2 ) and had significantly lower relative means compared with the ALSFRS leg subscore (Fig. 4) .
DISCUSSION
In this study, we demonstrated that 2 electrophysiological measures (mean-MUNIX and NI) successfully detected motor neuron loss in the presymptomatic limb of patients with ALS. In addition, the electrophysiological measures detected significant LMN loss prior to the development of fasciculations (the earliest clinical sign preceding weakness 25 ), atrophy, or weakness in the limb as assessed by a neuromuscular neurologist. Mean-MUNIX and NI also successfully tracked disease progression, showing a continuous loss of functional motor units during the presymptomatic interval, when weakness, atrophy, or fasciculation was undetectable to the patient and the evaluating clinician. During this presymptomatic interval, mean-MUNIX was the most sensitive parameter to demonstrate monthly changes, which validates the findings of Neuwirth et al. 15 in a well-defined subpopulation of patients with slowly progressive ALS. As previously described in MUNE studies, 26 absolute mean-MUNIX values below 70 in the TA, APB, and ADM increased the likelihood of detectable ALS, amyotrophic lateral sclerosis; ALSFRS-R, revised ALS Functional Rating Scale; ADM, abductor digiti minimi; APB, abductor pollicis brevis; CMAP, compound muscle action potential; HHD, hand-held dynamometer; LMN, lower motor neuron; mean-MUNIX, average of 3 consecutive MUNIX trials; MUNIX, motor unit number index; NI, neurophysiological index; TA, tibialis anterior.
*P < 0.05 (linear mixed-effect model).
LMN dysfunction on the clinical examination in this study, although relative longitudinal MUNIX changes are more reliable in ascertaining LMN involvement than absolute cutpoints. The APB had greater mean-MUNIX decline than the ADM, following the split-hand phenomenon, 27,28 and the HHD measures had a slight decline. This later finding of insidious loss of strength in the intrinsic hand muscles and finger flexors not captured by the fine motor functional subscore of the ALSFRS-R or manual muscle testing supports the use of HHD as an objective and sensitive strength measure and is in line with prior studies. 29, 30 As has been demonstrated in this study and in prior studies, 15, 29 clinical examination and ALSFRS-R subscores may erroneously display disease stability in the early phase of ALS because muscle strength can be maintained by compensatory mechanisms until more than 70% of the motor units are lost. 17, 31 Moreover, the duration of clinical measure stability may exceed the duration of a phase 2 study and is likely even longer in patients with slowly progressive disease (up to 15 months in our cohort). This feature likely contributes to false positive or negative endpoint measures, particularly when patients with slow and fast progressing disease are unbalanced in treatment arms. More sensitive surrogate candidate biomarkers such as mean-MUNIX and NI can overcome this limitation, increasing the likelihood of detecting a therapeutic signal in smaller and less costly ALS trials.
The development of reliable disease progression candidate biomarkers requires extensive analytic and clinical validation, which has previously been demonstrated for MUNIX and NI. Both single-trial MUNIX and MUNE have similar reproducibility in healthy controls and patients with ALS, as revealed by multiple single-center and multicentre studies. 7, 8, 11, 12, 32 Using the averaged values of 3 independent trials of MUNIX (mean-MUNIX) significantly improved reproducibility and precision in detecting longitudinal changes in patients with ALS. 23, 24 Our data also supported the favorable reproducibility of the NI, with low intraindividual variability. It is of particular note that the decline of mean-MUNIX and NI scores during the presymptomatic interval was significantly greater than the technical variability of these techniques, which supports their utility as disease progression measures.
The validation of MUNIX and NI as clinically meaningful measures of ALS disease progression was demonstrated longitudinally in symptomatic muscles, 16, 17, 33, 34 which correlates with ALSFRS-R decline. This would be difficult to confirm pathologically with repeated muscle biopsies given the logistical limitations. Mean-MUNIX and NI decline in clinically intact muscles is correlated with LMN loss. This is supported by a prior demonstration of single-MUNIX, needle EMG, and MUNE abnormalities preceding clinical signs of LMN involvement 3, 15, 26, 35, 36 and the absence of significant change in mean-MUNIX and NI scores in matched controls when retested after 3 months (EscorcioBezerra et al., 12 Supp. Info). As a result of these findings, NI has been used as an exploratory endpoint measure in an early phase trial of memantine in ALS, 37 and the single-MUNIX endpoint measure was included in an ALS clinical trial (NCT03296501) and in a large, multicentre observational study (NCT02611674).
For mean-MUNIX and NI to serve as disease progression biomarkers, a lead-in period of 3-4 months would be sufficient to capture the preintervention mean-MUNIX and NI decline rates, which can be compared with postintervention rates, as suggested by our data and prior studies. 15, 17 At a minimum, a study protocol should include mean-MUNIX of the APB and TA muscles along with NI or mean-MUNIX of the ADM. NI was found to be as sensitive as mean-MUNIX of the ADM muscle in detecting changes in the presymptomatic stage and has the advantage of using routine electrophysiological parameters. Among its limitations, the NI is restricted to the ADM muscle (in contrast to the MUNIX, which can assess multiple body regions), requires persistent F-waves (which can be absent in ALS), and requires control of hand temperature (because the NI relies on the CMAP distal latency). 38 Mean-MUNIX and NI could also improve our understanding of LMN loss in the preclinical phase of ALS. Long preclinical stages are well described in other neurodegenerative diseases, 39 and the presence and duration of this period in ALS remains uncharacterized. 4, 40 Identification of the preclinical stage may provide the optimal therapeutic window for interventions in the earliest phases of neurodegenerative diseases. A MUNE study demonstrated longitudinal decrease of motor unit number up to 10 months before the onset of symptoms in 2 of 19 asymptomatic individuals harboring SOD1 mutations. 26 MUNE, mean-MUNIX, and NI could be sensitive candidate surrogate measures in future trials in familial ALS because antisense oligonucleotides against pathogenic mutations such as SOD1 and C9ORF72 may be most efficacious in the preclinical phase.
Limitations of this study include the small ALS subpopulation sample and variable follow-up visit window. The inclusion of patients with slowly progressive ALS based on the assumption of normal ALFRS-R score at the time of disease onset is susceptible to recall bias; however, prospective changes in ALSFRS-R during this study confirmed the slow disease progression of the cohort. In addition, the restrictive inclusion criteria used here may reduce generalizability because it resulted in a study population with a higher proportion of bulbar-onset patients and women compared with the ALS population enrolled in clinical trials. As a single-center study, interrater variability was not assessed; however, this was not a significant technical limitation in a multicentre study investigating the MUNIX intraclass correlation coefficient in healthy individuals performed by trained MUNIX experts. 11 In addition, multicentre longitudinal MUNIX studies in ALS patients had reliable interrater reproducibility. 15, 35 In conclusion, this study expands on the utility of mean-MUNIX and NI as sensitive disease progression biomarkers in ALS. Over time, these measures were more sensitive than clinical measures in detecting change in presymptomatic muscles in a cohort of patients with slowly progressive ALS. Although functional measures like the ALSFRS-R remain important outcomes in clinical trials, electrophysiological measures should be included in early study phases to assist in the selection of the most promising compounds for pivotal trials.
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